Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma
FOXM1 inhibitor
animal models
combination therapy
nanoparticles
rhabdomyosarcoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
11
2022
accepted:
06
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Rhabdomyosarcoma (RMS) is a highly metastatic soft-tissue sarcoma that often develops resistance to current therapies, including vincristine. Since the existing treatments have not significantly improved survival, there is a critical need for new therapeutic approaches for RMS patients. FOXM1, a known oncogene, is highly expressed in RMS, and is associated with the worst prognosis in RMS patients. In the present study, we found that the combination treatment with specific FOXM1 inhibitor RCM1 and low doses of vincristine is more effective in increasing apoptosis and decreasing RMS cell proliferation
Identifiants
pubmed: 36816948
doi: 10.3389/fonc.2023.1112859
pmc: PMC9933126
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1112859Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Donovan, Deng, Bian, Shukla, Gomez-Arroyo, Shi, Kalinichenko and Kalin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2019 Sep 15;25(18):5548-5560
pubmed: 31175095
ACS Chem Neurosci. 2019 Mar 20;10(3):1801-1812
pubmed: 30609902
Theranostics. 2016 Aug 07;6(11):1887-98
pubmed: 27570558
Genes Chromosomes Cancer. 2009 Jun;48(6):455-67
pubmed: 19235922
Am J Respir Cell Mol Biol. 2021 Mar;64(3):292-307
pubmed: 33095997
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34768995
Clin Cancer Res. 2021 Sep 1;27(17):4923-4936
pubmed: 34145028
Cancers (Basel). 2021 Oct 21;13(21):
pubmed: 34771438
PLoS Genet. 2014 Sep 25;10(9):e1004656
pubmed: 25254494
Oral Dis. 2022 Oct;28(7):2052-2054
pubmed: 34592033
Cancer. 1969 Sep;24(3):520-6
pubmed: 4241949
Semin Cancer Biol. 2018 Oct;52(Pt 1):74-84
pubmed: 28855104
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W755-62
pubmed: 20513647
Theranostics. 2017 Jan 15;7(3):677-693
pubmed: 28255359
J Biol Chem. 2013 Aug 2;288(31):22527-41
pubmed: 23775078
Tumour Biol. 2016 Apr;37(4):5213-23
pubmed: 26553361
Oncogene. 2008 Jul 10;27(30):4137-49
pubmed: 18345025
Nanoscale. 2021 Aug 14;13(30):12966-12978
pubmed: 34477780
Cell Cycle. 2011 Feb 1;10(3):396-405
pubmed: 21270518
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Biochim Biophys Acta. 2012 Jan;1819(1):28-37
pubmed: 21978825
Adv Mater. 2017 Oct;29(40):
pubmed: 28873241
J Control Release. 2020 Aug 10;324:204-217
pubmed: 32389779
Mol Biol Cell. 2020 Jun 15;31(13):1411-1424
pubmed: 32348194
Oncogene. 2017 Feb 9;36(6):850-862
pubmed: 27425595
EMBO Rep. 2012 Dec;13(12):1095-101
pubmed: 23070364
Nanoscale. 2017 Jan 26;9(4):1457-1465
pubmed: 27942661
Adv Healthc Mater. 2019 Jan;8(2):e1801359
pubmed: 30549448
ACS Appl Mater Interfaces. 2018 Aug 1;10(30):25090-25098
pubmed: 29993234
Nano Lett. 2019 May 8;19(5):2914-2927
pubmed: 30929452
Cancer Res. 1982 Feb;42(2):535-9
pubmed: 7034923
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Nano Lett. 2018 Oct 10;18(10):6449-6454
pubmed: 30211557
Cancer Res. 2010 Jan 15;70(2):762-71
pubmed: 20068162
Cancer. 2009 Sep 15;115(18):4218-26
pubmed: 19536876
Front Bioeng Biotechnol. 2022 Oct 17;10:953555
pubmed: 36324885
Cancer Res. 2011 Jan 1;71(1):40-50
pubmed: 21199796
Sci Signal. 2018 Nov 20;11(557):
pubmed: 30459282
Adv Mater. 2018 Apr;30(17):e1705660
pubmed: 29504159
Mol Cancer Ther. 2019 Jul;18(7):1217-1229
pubmed: 31040162
Radiother Oncol. 2021 Feb;155:293-303
pubmed: 33096164
Elife. 2014 May 20;3:e02523
pubmed: 24844246
Am J Respir Cell Mol Biol. 2008 Oct;39(4):390-9
pubmed: 18421012
J Pain Res. 2020 Feb 07;13:323-329
pubmed: 32104054
Expert Opin Ther Targets. 2015 Jul;19(7):865-7
pubmed: 25936405
Expert Opin Investig Drugs. 2010 Feb;19(2):235-42
pubmed: 20074015
Hum Pathol. 2014 Sep;45(9):1900-9
pubmed: 25086956
Pediatr Blood Cancer. 2019 Aug;66(8):e27820
pubmed: 31099166
Int J Mol Sci. 2019 Sep 23;20(19):
pubmed: 31547569
Adv Healthc Mater. 2018 Dec;7(23):e1800876
pubmed: 30398703
PLoS One. 2013 Sep 26;8(9):e73881
pubmed: 24086299
Cell Rep. 2018 Apr 10;23(2):442-458
pubmed: 29642003
PLoS One. 2015 Mar 26;10(3):e0121806
pubmed: 25811876
ACS Appl Mater Interfaces. 2020 Dec 23;12(51):57410-57420
pubmed: 33289538
PLoS One. 2009 Aug 12;4(8):e6609
pubmed: 19672312
Mol Ther Oncolytics. 2015 Jan 21;1:14010
pubmed: 27119100
J Biol Chem. 2015 Mar 20;290(12):7563-75
pubmed: 25631042
Mol Cancer Ther. 2008 Jul;7(7):2022-32
pubmed: 18645012
Front Pharmacol. 2021 Feb 03;12:601626
pubmed: 33613290
Oncogene. 2021 Mar;40(12):2182-2199
pubmed: 33627785
J Exp Clin Cancer Res. 2019 Mar 8;38(1):118
pubmed: 30850026
Oncogene. 2012 Aug 23;31(34):3875-88
pubmed: 22139074
PLoS Genet. 2017 Dec 21;13(12):e1007097
pubmed: 29267283
Sci Signal. 2017 Apr 18;10(475):
pubmed: 28420758
Int J Gynecol Pathol. 2021 Sep 1;40(5):501-509
pubmed: 33323854
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
ACS Nano. 2008 Aug;2(8):1696-702
pubmed: 19206374